ArticleCancer immunology, immunotherapy : CII2021
Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer.
Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- VISTA: bridging gaps in cancer immunotherapy.Discover oncology · 2026Review
- The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.Biomarker research · 2025Review
- The tumor microenvironment's role in the response to immune checkpoint blockade.Nature cancer · 2025Review
- Targeting MAPK14 by Lobeline Upregulates Slurp1-Mediated Inhibition of Alternative Activation of TAM and Retards Colorectal Cancer Growth.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Immune snapshots along the inflammation-to-cancer road in bladder urothelium.Frontiers in immunology · 2025Review
- [Advances of Fundamental Research on Traditional Chinese Medicine in Regulation of Tumor-associated Macrophages for the Prevention and Treatment of Lung Cancer Metastasis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- B-cell performance in chemotherapy: Unravelling the mystery of B-cell therapeutic potential.Clinical and translational medicine · 2024Review
- LRIG1 engages ligand VISTA and impairs tumor-specific CD8Science immunology · 2024Article
- Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Article
- Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.BMC cancer · 2023Article
- Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors.Frontiers in immunology · 2023Review
- Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.Frontiers in immunology · 2023Review
- Immune cellular components and signaling pathways in the tumor microenvironment.Seminars in cancer biology · 2022Review
- The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy.Cancers · 2022Article
- The complex role of tumor-infiltrating macrophages.Nature immunology · 2022Review
- IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.Biomarker research · 2022Review
- Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.Biomedicines · 2022Review
- Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma.Frontiers in oncology · 2022Article
- Development and Validation of Ferroptosis-Related LncRNA Biomarker in Bladder Carcinoma.Frontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint molecule expressed in hematopoietic cells, granulocytes, macrophages, and monocytes. However, few studies to date have investigated VISTA expression, especially its clinical utility, in bladder cancer. The present retrospective study aimed to examine VISTA, programmed death ligand-1 (PD-L1), and CD45 expression by immunohistochemical and immunofluorescence staining of archived pathological tissue samples from 159 patients with primary bladder cancer. The correlation between VISTA expression in immune cells (ICs) and clinicopathologic variables including PD-L1 expression in ICs was examined. Briefly, the rates of VISTA-positive ICs and VISTA-positive tumor cells were 67.9% (108/159) and 30.8% (49/159), respectively. The VISTA expression in ICs of patients with bladder cancer, including those with non-muscle-invasive bladder cancer (NMIBC), was positively correlated with tumor stage, grade, size, and multiplicity. The VISTA expression in ICs was stronger in bladder cancer cases with PD-L1-positive ICs than in those with PD-L1-negative ICs (p < 0.001). The mean intravesical recurrence-free survival was shorter in NMIBC cases with VISTA-positive ICs than in those with VISTA-negative ICs (34.0 vs 39.9 months, p = 0.03, log-rank test). In this first study to investigate VISTA expression in bladder cancer, these results implicate VISTA as a potential immunotherapeutic target and immunologic biomarker in bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.